We found a stable profile of mRNA expression for MMP-2 and 3, TIMP-2 and -3, and a slight decline for the MMP-1 and TIMP-1 and -2 profiles during the differentiation of ASCs to osteocytes, which predispose these cells to future therapy in bone disorders. The gene discussed is TIMP2; the disease is bone disorder.